Trials / Terminated
TerminatedNCT02558114
Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.
Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the efficacy, safety and recurrence rate of two therapeutic strategies with ribavirin in patients with chronic hepatitis E and severe acute hepatitis E: fixed duration of treatment for 12 weeks vs variable duration depending on the viremia within 4 weeks of the start of treatment (12 vs 24 weeks). The purpose of the study is also improve the safety of treatment with Ribavirin by optimizing dose adjusted to renal function, plasma levels of drug and hemoglobin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ribavirin |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2015-09-23
- Last updated
- 2019-04-16
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02558114. Inclusion in this directory is not an endorsement.